• Sat. Dec 7th, 2024

Novo Nordisk (NVO): Momentum Continues While Valuation Remains ‘Not Too’ Expensive

Byadmin

Jan 15, 2023
Mike Zaccardi, CFA, CMT profile picture

[ad_1]

puhimec

Pharmaceutical stocks have been a nascent space of safety and growth in a volatile market over the last year plus. The group rallied hard on a relative basis during the first half of 2022, but then gave back some of those relative

[ad_2]

Image and article originally from seekingalpha.com. Read the original article here.